Q2 FY2026 · ended Jun 30, 2026 · Revenue $190.70M, -10.5% YoY · Filed Jul 31, 2026
Myriad Genetics, Inc. (MYGN) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $190.7 million and a net loss of $43.2 million. As of Jun 30, 2026 it held $115.2 million in cash and investments and $210.5 million in total debt.
Revenue
$190.70M
-10.5% vs year-ago quarter
Net income
$-43.20M
+86.9% vs year-ago quarter
Operating cash flow
$-8.30M
+39.0% vs year-ago quarter
Free cash flow
—
EPS
$-0.46
+87.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
95.65M
+2.8% vs year-ago quarter
Net cash
$-95.30M
Q2 FY2026
Operating margin
-12.2%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- MYGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 899923
- Former names
- MYRIAD GENETICS INC (until Nov 6, 2026)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $190.7M | $200.4M | $209.8M | $205.7M | $213.1M |
| Operating income | -$38.9M | -$30.7M | -$5.7M | -$23.3M | -$329.2M |
| Net income | -$43.2M | -$34.1M | -$7.9M | -$27.4M | -$330.5M |
| Diluted EPS | -$0.46 | -$0.36 | -$0.08 | -$0.29 | -$3.57 |
| Operating cash flow | -$8.3M | -$15.7M | $10.6M | $21.1M | -$13.6M |
| Total assets | $638.9M | $673.7M | $706.6M | $728.1M | $677.3M |
| Total liabilities | $335.0M | $336.3M | $338.6M | $355.3M | $289.2M |
| Stockholders' equity | $303.9M | $337.4M | $368.0M | $372.8M | $388.1M |
| Cash and investments | $115.2M | $124.4M | $149.6M | $145.4M | $74.4M |
| Total debt | $210.5M | $211.5M | $209.8M | $212.3M | $154.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 6, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 20, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 9, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 16, 2026 | Sep 15, 2026 |
All 1000 Myriad Genetics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.